Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

Trump previously selected Robert Francis Kennedy Jr. to head up the Department of Health and Human Services—the NIH’s parent ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

The biotech is focused on signing on the dotted line before the end of the year, said CEO André Muller, who explained that ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

On the heels Kronos Bio’s decision to can its last remaining clinical asset earlier this month, the company said it would ...

A federal court jury has sided with Guardant Health, which had claimed that rival cancer test developer Natera went too far ...

The academic-led, industry-partnered collaboration Equitable Breakthroughs in Medicine Development (EQBMED) has released an ...

Neuralink said it has received a green light for a new clinical study to test the feasibility of connecting its ...